Medtronic, IBM Watson Health add low-glucose predictions to diabetes app

Medtronic added a predictive feature to Sugar.IQ, its diabetes management app.

Medtronic released Sugar.IQ in partnership with IBM Watson Health in June. The Sugar.IQ app, which is available to users of Medtronic's Guardian Connect continuous glucose monitoring system via Apple's App Store, uses artificial intelligence and analytics from IBM Watson Health to analyze how certain foods, insulin dosages and daily routines influence a user's glucose levels.

The new feature — dubbed IQcast — predicts the likelihood of a user experiencing a low-glucose event up to four hours in advance, supporting Medtronic and IBM Watson Health's goal of providing patients with personalized guidance to manage their diabetes.

"Simply put, IQcast acts like a weather forecast for people with diabetes so they can better prepare for their day," said Robert Vigersky, MD, senior director of medical and clinical affairs for the diabetes group at Medtronic.

More articles on artificial intelligence:
Apple promotes AI chief to exec team: 4 things to know
AI can re-identify de-identified health data, study finds
NYU School of Medicine releases 10K MRI scans as part of Facebook collaboration

© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Whitepapers

Featured Webinars